#abbvie — Public Fediverse posts

ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression

AbbVie ABBV has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter’s lead pipeline…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Mentalhealth #ABBV #AbbVie #GilgameshPharmaceuticals #Health #MADRS #MentalHealth #ZacksInvestmentResearch
https://www.newsbeep.com/us/115696/

ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression

AbbVie ABBV has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter’s lead pipeline…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Mentalhealth #ABBV #AbbVie #GilgameshPharmaceuticals #Health #MADRS #MentalHealth #ZacksInvestmentResearch
https://www.newsbeep.com/us/115696/

https://www.europesays.com/uk/377986/ ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression #ABBV #AbbVie #GilgameshPharmaceuticals #Health #MADRS #MentalHealth #UK #UnitedKingdom #ZacksInvestmentResearch

ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression

AbbVie ABBV has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter’s lead pipeline…
#NewsBeep #News #Mentalhealth #ABBV #AbbVie #GilgameshPharmaceuticals #Health #MADRS #MentalHealth #UK #UnitedKingdom #ZacksInvestmentResearch
https://www.newsbeep.com/uk/96577/

AbbVie (ABBV)

#Tradingan - #Grafik #harga #saham #AbbVie (ABBV) hari ini untuk membantu #analisa #pasar sebelum memulai #investasi dan #trading saham AbbVie #ABBV. AbbVie Inc. (NYSE: ABBV) adalah #perusahaan #biofarmasi global yang berfokus pada #pengembangan dan #komersialisasi obat-obatan #inovatif, terutama di bidang #imunologi, onkologi, neurosains, dan virologi. Perusahaan ini terkenal berkat obat Humira, salah satu obat terlaris di dunia untuk penyakit autoimun…

https://tradingan.com/abbvie

Microsoft's stock decline deemed unwarranted by analyst, who highlights company's solid business performance and growth potential amid tech sector volatility
#YonhapInfomax #Microsoft #MagnificentSeven #StockPerformance #Spotify #AbbVie #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=61080

US pharmaceutical giants face potential tariff risks as Trump administration considers imposing up to 25% tariffs on imported drugs, with Merck, AbbVie, Amgen, and Pfizer identified as most vulnerable.
#YonhapInfomax #TrumpTariffs #PharmaceuticalIndustry #Merck #AbbVie #ImportedDrugs #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=56730

Dividend-focused ETF SCHD gains attention as New York stock market correction increases its yield, offering attractive investment opportunity amid market volatility
#YonhapInfomax #SCHD #DividendYield #NewYorkStockMarket #HighDividendStocks #AbbVie #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=54379

5 neuro data readouts to watch in the second half of 2024 — GSK moves to new HQ in return to central London — AbbVie led the way in paying doctors to pitch its drugs last year —http://bit.ly/w28kSd #clinicaltrials #neurology #gsk #london #abbvie #physicians #physicianpayments #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AbbVie's tight grip on Humira market raises concerns about biosimilars—As biotech recovers, venture firms’ preferences appear to shift — Boehringer, Zealand heat up MASH race with strong phase II data—http://bit.ly/w28kSd #abbvie #humira #biosimilars #funding #mash #nash #boehringeringelheim #ipos #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AbbVie (#ABBV) reported an actual EPS of $2.31, slightly higher than the forecasted $2.27. Additionally, its revenue beat expectations, with actual revenue at $12.31 billion compared to the forecasted $11.93 billion. #AbbVie #earnings

AbbVie (#ABBV) reported an actual EPS of $2.31, slightly higher than the forecasted $2.27. Additionally, its revenue beat expectations, with actual revenue at $12.31 billion compared to the forecasted $11.93 billion. #AbbVie #earnings

J&J narrowly misses Q1 revenue on lower-than-expected Stelara sales—Humira biosimilar scripts take off—Intra-Cellular launches 26% to record high, breaking out after depression drug scores big--http://bit.ly/w28kSd #earnings #jnj #abbvie #humira #biosimilars #depression #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J narrowly misses Q1 revenue on lower-than-expected Stelara sales—Humira biosimilar scripts take off—Intra-Cellular launches 26% to record high, breaking out after depression drug scores big--http://bit.ly/w28kSd #earnings #jnj #abbvie #humira #biosimilars #depression #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

J&J narrowly misses Q1 revenue on lower-than-expected Stelara sales—Humira biosimilar scripts take off—Intra-Cellular launches 26% to record high, breaking out after depression drug scores big--http://bit.ly/w28kSd #earnings #jnj #abbvie #humira #biosimilars #depression #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff— What ancient art form has inspired many technological advances for medical devices? — FDA delays review of BioMarin's hemophilia gene therapy after data update-- See more on our front page news http://bit.ly/w28kSd #abbvie #pharmaceos #patents #devices #meddevice #medtech #productdesign #hemophilia #biomarin #genetherapy #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma